Valion Bio, Inc. VBIO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 302.00K | 482.00K | 462.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 302.00K | 482.00K | 462.00K |
| Cost of Revenue | -- | -- | 291.00K | 710.00K | 501.00K |
| Gross Profit | -- | -- | -145.00K | -384.00K | -195.00K |
| SG&A Expenses | -- | -- | 4.77M | 4.52M | 4.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 7.90M | 7.41M | 6.34M |
| Operating Income | -- | -- | -7.90M | -7.08M | -6.03M |
| Income Before Tax | -- | -- | -7.99M | -7.12M | -5.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -7.99 | -7.12 | -5.96 |
| Earnings from Discontinued Operations | -- | -- | -885.00K | -385.00K | -385.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -8.88M | -7.51M | -6.34M |
| EBIT | -- | -- | -7.90M | -7.08M | -6.03M |
| EBITDA | -- | -- | -7.89M | -7.08M | -6.03M |
| EPS Basic | -- | -- | -197.14 | -247.81 | -296.04 |
| Normalized Basic EPS | -- | -- | -110.57 | -147.04 | -179.11 |
| EPS Diluted | -- | -- | -197.14 | -247.81 | -296.04 |
| Normalized Diluted EPS | -- | -- | -110.57 | -147.04 | -179.11 |
| Average Basic Shares Outstanding | -- | -- | 158.10K | 130.40K | 92.20K |
| Average Diluted Shares Outstanding | -- | -- | 158.10K | 130.40K | 92.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |